Psychedelics For Major Depressive Disorder And Anxiety Disorders: Data Suggests Cybin's Deuterated Analogs Could Work

Cybin Inc CYBN recently provided updates on its innovative treatments for Major Depressive Disorder (MDD) and Anxiety Disorders during its Investor Day. The company is developing proprietary, deuterated analogs of psilocybin and DMT molecules to address the growing need for effective mental health treatments.

MDD Treatment

MDD is the leading cause of death related to mental health, with approximately 2,000 people dying by suicide every day. The World Health Organization (WHO) and the Global Burden of Disease study estimate that almost 800,000 people die from suicide every year: That’s roughly one person every 40 seconds.

Depression and alcohol are the primary contributors to suicidality, and MDD presents a $210 billion economic burden on the U.S. alone. Unfortunately, only one-third of patients benefit from current treatment options.

During its investor day, Cybin revealed that its CYB003 program for MDD has reached a significant milestone, with Phase 1/2a interim data readout confirming the results observed in preclinical studies.

These findings include a fast onset and short duration of effect, low variability in plasma, and low dose levels. The interim data also indicate a positive safety and tolerability profile, with robust psychedelic effects observed at low dose ranges.

The Phase 1/2a topline data is expected in late Q3 2023.

Anxiety Disorders Treatment

Anxiety disorders affect 18% of the U.S. population and over 300 million people worldwide, making them a major global health concern.

Cybin is developing CYB004, a proprietary deuterated DMT molecule, as a potential treatment for these disorders. Current treatments, such as sedatives, SSRIs, SNRIs and psychotherapy, often have delayed response times, with 50% of patients not responding to first-line treatment.

Key highlights of the CYB004 program include the completion of Part A of the Phase 1 CYB004-E clinical trial, which showed that IV DMT was well-tolerated with no safety issues. Dose-related increases in both DMT exposure and behavioral effects were observed. The study design has been expanded to include first-in-human dosing of CYB004, aiming to accelerate clinical development and gain a better understanding of the optimal dosing regimen.

The Phase 1 topline data, including DMT and CYB004, is expected in Q3 2023.

Benzinga Psychedelics Capital Conference

The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey.

Scheduled for April 13th, this year's edition follows the well-established Cannabis Capital Conference (CCC) and will take place at the luxurious Fontainebleau Miami Beach Hotel in Florida. The conference boasts an impressive lineup of keynote speakers and specialized leaders in psychedelics advisory, including people from tye Cybin team, who will be discussing the latest trends and innovations in the field.

Photo by Noah Silliman on Unsplash